Suraksha Diagnostic Targets 35% EBITDA Margin by Midterm

Suraksha Diagnostic Limited — Q4 & FY26 Earnings Call (FY ended 31 Mar 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “exceptionally strong note”, “very strong”, “stellar… repeatable structural growth”, and “clear runway for future profitability”.
• They project margin recovery and operating leverage with confidence (e.g., “midterm we will stabilize at 35%”, “in the long term… 38%, 39%”).

2. Key Themes from Management Commentary

• Network expansion with hub-and-spoke model: FY26 added 2 hubs, 11 spokes, and 3 PPP centers, taking centers to 68 (as of Mar 2026).
• Technology-led differentiation & scaling genomics/molecular diagnostics:
• Genomics positioned as a “very important pillar”.
• Acquisition of Genexus NGS platform in Eastern India; faster turnaround (48–72 hours vs 14–21 days).
• Plans to scale into whole genome testing, metagenomics, AI integration, and population screening.
• Radiology capability upgrades & throughput improvements:
• Helium-free 1.5T MRI integration at Calcutta Medical College (zero helium dependency, lower downtime, faster throughput).
• Roche pathology automation enabling 3x more output; labs “online and on a platform”.
• Specialty clinics & preventive screening initiatives: dementia/epilepsy clinics; gyne-owned clinics; cervical/ovarian cancer early detection campaign.
• Margin narrative tied to maturity/operating leverage:
• Mature centers deliver 36–37% EBITDA margin consistently.
• Blended margin pressured by new center ramp-up and pre-operative costs; management expects improvement as centers mature.

3. Q&A Analysis

Theme A: Margins—trajectory, drag from new centers, and medium-term targets

• Core questions:
• Can EBITDA margins recover from FY26 decline (33.8% → 31.8%)?
• How much drag is from new centers / pre-operative expenses?
• What is “normalized” margin potential once centers mature?
• Management response:
• Mature centers: “continue to deliver 36%, 37%”.
• Mid-term stabilization: “stabilize at around 35%”; long-term “around 38%, 39%”.
• Drag explanation: “fixed cost has increased for the new centers” and “pre-operative expenses… give it a hit”.
• Breakeven timing: small centers 5–6 months, big centers 9–12 months (center level), plus 1–2 additional quarters to breakeven at HO expense level.
• Notable/partial or evasive elements:
• Quantification of margin drag remained high-level (“fixed cost”, “pre-operative expenses”) without a clean bridge to the exact EBITDA margin delta.
• Some answers were repetitive and relied on maturity/operating leverage rather than new cost levers.

Theme B: Center expansion plan—timing, elections/licensing delays, and capex

• Core questions:
• Impact of elections on center openings.
• Whether prior guidance on center additions was missed and why.
• FY27 center rollout details and capex.
• Management response:
• Elections: only “some of our centers… got a little delayed”.
• Center count: FY26 ended at 68; target to reach 100 by FY28; FY27 planned 14 openings (as discussed in Q&A).
• FY27 capex: “around INR70 crores” for 5 hubs and 8 asset-light spokes (management also referenced that some capex was already incurred due to delays).
• Notable/partial elements:
• The call acknowledges delays, but does not provide a precise reconciliation of “planned vs actual” center openings beyond election/licensing explanations.

Theme C: Patient growth quality—low Q4 patient growth vs strong revenue growth

• Core questions:
• Q4 patient growth was modest (~1.7%); why?
• Is patient growth metric flawed? What explains revenue per patient spike?
• Management response:
• They challenged the metric: patient counts are “not a very definite matrix” due to lack of unique patient ID; spelling/IT hygiene issues can inflate/deflate patient counts.
• Revenue per patient spike attributed to genomic tests and specialized radiology tests (higher priced).
• Notable/strong/evasive elements:
• Strong admission that patient growth is measurement-imperfect (“flawed matrix”), which reduces comparability vs peers.
• No alternative KPI was offered (e.g., unique members, visit-based metrics) to replace patient growth.

Theme D: Genomics business—run rate, contribution, and margins

• Core questions:
• Current genomics run rate and future trajectory.
• Expected revenue contribution by FY28 and whether margins are sustainable.
• Management response:
• Genomics run rate: cited ~INR35 lakhs per month (Q4 incremental discussion).
• FY27 genomics growth: referenced incremental quarter performance; no full quantitative FY27 genomics revenue guide beyond run-rate.
• Margins: “till… achieve some economies of scale… any margin… would not be right”.
• Notable/partial elements:
• Genomics margin guidance is explicitly withheld pending scale, which limits visibility.

Theme E: Operational details—utilization, cannibalization, and mix

• Core questions:
• Cannibalization in Kolkata clusters as density increases.
• Utilization levels for MRI/CT.
• Radiology vs pathology growth expectations.
• Management response:
• Cannibalization: “Not really”; expects regional growth; center-to-center dip 5–10% but new centers ramp faster.
• Utilization: they do not break out realization/utilization cleanly (“do not really break our realization levels”).
• Mix: radiology expected to remain around industry prescription split; “around the industry numbers only”.
• Notable/partial elements:
• Utilization/throughput is discussed qualitatively, but no hard utilization metrics were provided.

Theme F: Cost structure—other expenses, rentals, and professional fees

• Core questions:
• What drives professional fees to doctors?
• Rental cost and other expense composition.
• Management response:
• Professional fees: radiologists/pathologists + OPD consultation fees; “retain 15% and… pay back 85%”.
• Rentals: rental cost referenced as “around INR30 crores” (FY27 context in one question) and other expense drivers were linked to new rentals and pre-operative ramp.
• Notable/partial elements:
• One question on “% of other expenses attributable to capex/pre-operative” was deferred: “we will have to get back…” (no follow-up in transcript).

4. Guidance / Outlook

Explicit guidance (quantitative)

• FY27 revenue growth: “Around 15%” (also reiterated: “commitment is 15%”).
• FY27 EBITDA margin: management guided stabilize around ~33% (Q&A: “stabilize at around 33%”).
• Medium/long-term EBITDA margin targets (qualitative but with numbers):
• Mid-term: “around 35%”
• Long term: “38%, 39%”
• Capex for FY27: “around INR70 crores”
• Center additions for FY27 (implied by Q&A):
• “three new hubs and eight asset-light spoke centers within West Bengal”
• plus “one specialized hub center each in Bihar, Tripura, and Jharkhand” (as stated in opening/CEO plan)
• Genomics run rate: “INR35 lakhs per month” (run-rate reference, not formal guidance)

Implicit signals (qualitative)

• Margin pressure is expected to persist near-term due to new center ramp-up and pre-operative expenses; improvement depends on operating leverage and cost efficiency (centralized procurement, sweating automation).
• They are prioritizing scale first, margins second (“need the scale today” / “conscious call” in earlier call; echoed in this call via margin dilution explanation).

5. Standout Statements (direct quotes where useful)

• On profitability runway: “The gap between our mature margins and blended margins represents a clear runway for future profitability.”
• On FY27 margin stabilization: “For FY27, the EBITDA margin would stabilize at around 33%.”
• On medium/long-term margin: “midterm we will stabilize at 35%” and “in the long term… 38%, 39%.”
• On center ramp-up economics: “small centre… breakeven… around five to six months” and “big centre… nine to 12 months… plus one to two quarters at HO expense level.”
• On patient metric credibility: “patient growth is not a very definite matrix” and “a very flawed matrix” due to lack of unique patient ID.
• On genomics turnaround advantage: Genexus results in “48 to 72 hours instead of… 14 to 21 days.”
• On elections impact: “The only impact… was some of our centers… got a little delayed.”

6. Red Flags / Positive Signals

Red flags
– Patient growth metric reliability questioned: management admits patient counts can be distorted by IT/registration hygiene (“flawed matrix”), making peer comparisons harder.
– Margin guidance is conditional and delayed: near-term stabilization (~33%) but recovery relies on ramp-up; limited hard cost-lever quantification.
– Deferred disclosure: one question on the % of other expenses attributable to capex/pre-operative was not fully answered (“we will have to get back”).
– Genomics margin visibility limited: explicitly says margins can’t be stated until economies of scale.

Positive signals
– Clear maturity economics: mature centers consistently at 36–37% EBITDA margin.
– Concrete operational investments: MRI tech upgrade (helium-free), Roche automation, online labs—linked to throughput and efficiency.
– Run-rate disclosure for genomics: provides at least a monthly figure (~INR35 lakhs/month).

7. Historical Comparison & Consistency Analysis (vs prior 3 calls provided)

a. Change in Tone Over Time

• Current call (May 2026): more confident/optimistic, emphasizing “exceptionally strong note” and “clear runway”.
• Prior calls:
• Nov 2025 (Q2/H1): optimistic but more defensive around margin pressure from rain/floods and new center dilution; still guided FY26 EBITDA margin 33–34%.
• Feb 2026 (Q3/9M): optimistic on topline; acknowledged margin compression due to pre-operative costs; expected margins to revert as centers mature.
• Classification: More Optimistic than earlier calls.
• What changed: management now highlights technology upgrades (Genexus, helium-free MRI, Roche automation) and provides more numerical medium/long-term margin targets (35% / 38–39%) rather than only “revert to normal”.

b. Tracking Past Commitments vs Outcomes

1) FY26 EBITDA margin guidance (Nov 2025): “EBITDA margin between 33% to 34%”
– Expected: ~33–34% for FY26.
– Actual (May 2026): FY26 EBITDA margin 31.8%.
– Flag: ❌ Missed (below guided range).

2) FY26 revenue growth guidance (Nov 2025): “15% revenue growth in FY26”
– Expected: ~15% YoY.
– Actual (May 2026): FY26 revenue growth 22.5% YoY.
– Flag: ✅ Delivered / Over-delivered.

3) Center addition cadence (Nov 2025): “on track to adding 12 to 15 centres this financial year”
– Expected: 12–15 own centers (management later clarified definitions).
– Actual (May 2026): centers reached 68 by Mar 2026; Q&A references delays and different counting (own vs PPP vs Fetomat).
– Flag: ⏳ Partially delivered / definition-dependent (management acknowledged delays; no clean reconciliation to the “12–15” own-center commitment in this transcript).

4) Genomics run-rate (Feb 2026): genomics run rate discussed around INR2.1–2.2 million/month (and Q3 reached ~INR53 lakhs)
– Current (May 2026): genomics run-rate cited as INR35 lakhs/month (and incremental Q4 incremental discussion).
– Flag: ⏳ Mixed / unclear (numbers appear inconsistent; could be timing/definition differences, but transcript does not reconcile).

c. Narrative Shifts

• From “genomics as new black / moat” (Feb 2026) → to “genomics as a pillar with specific tech and turnaround advantage” (May 2026).
• Margin explanation evolves:
• Earlier: heavy emphasis on seasonality/floods (Nov 2025) and “pre-operative costs” (Feb 2026).
• Now: more emphasis on structural moat + maturity runway, while still admitting near-term dilution.
• Patient growth discussion becomes more defensive in May 2026: management now explicitly calls patient growth a flawed metric—this is a notable shift from earlier calls where patient growth was treated as a key KPI.

d. Consistency & Credibility Signals

• Medium credibility (not high):
• Over-delivery on revenue vs under-delivery on EBITDA margin vs earlier guidance.
• Patient growth metric credibility was challenged only in the latest call, which can be seen as post-hoc framing.
• Margin targets for FY27 are given, but FY26 margin miss reduces confidence in near-term margin precision.

e. Evolution of Key Themes

• Demand/growth: improving/strong—revenue growth remains high (23% FY26).
• Margins: deteriorated vs earlier guidance (33–34% → 31.8%), but management claims recovery via maturity.
• Expansion: consistent hub-and-spoke strategy; continued multi-state push (now explicitly into Bihar/Tripura/Jharkhand).
• Technology differentiation: increasing specificity and investment detail over time (Genexus, helium-free MRI, Roche automation).

f. Additional Insights (Cross-Period Intelligence)

• A gradual shift from “margin will revert” (Nov/Feb) to “margin will stabilize at 33%” (May) suggests management may be recalibrating expectations due to ramp-up duration/cost structure.
• The patient growth KPI credibility issue emerging in May 2026 may indicate that volume growth is not as strong as center-count growth would imply, or that measurement changes are masking underlying softness.

End of report